Fulcrum Therapeutics, Inc.
FULC
$6.92
-$0.51-6.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 20.80% | -2.34% | -24.76% | -32.21% | -347.49% |
| Gross Profit | -20.80% | 2.34% | -120.70% | 32.21% | 359.38% |
| SG&A Expenses | -5.69% | -10.23% | -33.37% | -30.43% | -21.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.80% | -5.22% | -27.97% | -31.61% | -32.69% |
| Operating Income | -16.80% | 5.22% | -137.75% | 31.61% | 30.59% |
| Income Before Tax | -22.73% | 9.68% | -131.22% | 34.29% | 33.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.73% | 9.68% | -131.22% | 34.29% | 33.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.73% | 9.68% | -131.22% | 34.29% | 33.07% |
| EBIT | -16.80% | 5.22% | -137.75% | 31.61% | 30.59% |
| EBITDA | -17.24% | 5.21% | -136.83% | 31.70% | 30.65% |
| EPS Basic | -0.65% | 9.95% | -131.04% | 34.81% | 23.24% |
| Normalized Basic EPS | -0.68% | 0.51% | -131.04% | 34.81% | 23.27% |
| EPS Diluted | -0.35% | 10.57% | -132.18% | 34.81% | 22.49% |
| Normalized Diluted EPS | -0.68% | 0.51% | -131.73% | 34.81% | 23.27% |
| Average Basic Shares Outstanding | 21.92% | 0.30% | 0.54% | 0.80% | -12.80% |
| Average Diluted Shares Outstanding | 21.92% | 0.30% | -1.64% | 0.80% | -12.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |